- Home
- CMCL vs ALLO Comparison
CMCL vs ALLO Comparison
Compare CMCL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMCL | ALLO |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.1M | 452.6M |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CMCL | ALLO |
|---|---|---|
| Price | $21.61 | $1.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $43.88 | $9.00 |
| AVG Volume (30 Days) | 179.8K | ★ 8.7M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.19 | N/A |
| Revenue Next Year | $6.55 | $216.23 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.85 | $1.07 |
| 52 Week High | $34.00 | $4.46 |
Technical Indicators
Market Signals| Indicator | CMCL | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 29.01 |
| Support Level | $21.12 | N/A |
| Resistance Level | $21.80 | $2.25 |
| Average True Range (ATR) | 0.95 | 0.10 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 49.52 | 13.75 |
Price Performance
Historical ComparisonAbout CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).